BRADLEY PHARMACEUTICALS (BPRXA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BRADLEY PHARMACEUTICALS (BPRXA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Brad Glassma	3/25/1996 1:03:00 PM
	of 41

No, it's just the simple fact that for MERCK, SANDOZ, AHP, or etc. it doesn't make sense for them to hold on to products that only generate a couple of million in sales, even if they are profitable. These products tie up factories and grow SGA-- especially when you consider that these companies usually control several $500 million products. However, BRADLEY's marketing expertise and technical know-how can grow a $2 million product into a $5 million product. This substantial growth will continue to fuel BRADLEY and provide generous growth for the firm in the future.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next